Key regions: Germany, South Korea, France, United States, United Kingdom
The use of Anti-Coagulants has been increasing in the United States in recent years.
Customer preferences: Patients in the United States are increasingly choosing Anti-Coagulants as a treatment option due to their effectiveness in preventing blood clots and reducing the risk of stroke. Additionally, the convenience of oral administration compared to traditional injectable options has also contributed to the growing popularity of Anti-Coagulants.
Trends in the market: One of the major trends in the Anti-Coagulants market in the United States is the shift towards newer oral Anti-Coagulants, such as Factor Xa inhibitors and direct thrombin inhibitors. These drugs have been gaining popularity due to their improved safety profile and ease of use compared to traditional Anti-Coagulants. Another trend in the market is the increasing use of Anti-Coagulants for indications beyond the traditional treatment of deep vein thrombosis and pulmonary embolism, such as in the prevention of stroke in patients with atrial fibrillation.
Local special circumstances: The United States has a large and aging population, which has contributed to the growing demand for Anti-Coagulants. Additionally, the high prevalence of conditions such as atrial fibrillation and venous thromboembolism has also driven the growth of the market. The presence of a well-established healthcare system and high levels of healthcare expenditure have also facilitated the adoption of Anti-Coagulants in the country.
Underlying macroeconomic factors: The Anti-Coagulants market in the United States is also influenced by macroeconomic factors such as healthcare policies and regulations. The increasing focus on value-based care and cost containment has led to greater scrutiny of the pricing of Anti-Coagulants, which has put pressure on manufacturers to offer competitive pricing. Additionally, the increasing use of generic Anti-Coagulants has also contributed to the growth of the market by making these drugs more affordable and accessible to patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
